BOSTON, April 8 (Reuters) - Nexium, AstraZeneca 's drug developed to fight acid reflux and widely prescribed for decades to quell the symptoms of asthma, does little to help adults breathe easier, ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) announced today that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM ® I.V. (esomeprazole sodium) for Injection ...

The Food and Drug Administration has approved use of the drug Nexium in children aged 1 to 11 who have acid reflux disease. FDA said Thursday it approved liquid and delayed-release capsules of Nexium ...

Gastro-Esophageal Reflux Disease (GERD) is one of the most prevalent diagnoses and the most treated diseases. People are desperate for relief and taking drugs to try to mitigate their symptoms.

AstraZeneca has submitted a new drug application asking for approval to market Nexium for babies less than one year old. The company believes the drug is an appropriate short-term, second-line ...

WILMINGTON, Del., July 15, 2013 /PRNewswire/ -- Acid reflux disease, also known as gastroesophageal reflux disease (GERD), is one of the most common chronic illnesses in the US today, affecting more ...

The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease or GERD. The agency ...

Gastroesophageal reflux is a condition that can cause heartburn symptoms. Heartburn is described as a burning sensation felt in the center of the chest, and occurs when acid from the stomach is forced ...

Both laparoscopic anti-reflux surgery and proton pump inhibitors such as Nexium provide long-term control of gastroesophageal reflux disease, commonly known as GERD, French researchers reported ...

“Knowing if your child has GERD can be difficult to spot,” says Mark Gilger, MD, Pediatrician-in-Chief at the Children’s Hospital of San Antonio. “Young children suffering from GERD may not be able to ...

In an attempt to slow down use of the drug that would become the second-highest-grossing pharmaceutical in the United States, the head of Medicaid and Medicare delivered a blunt admonition to a 2003 ...